UNIVERSITAT POMPEU FABRA - Coordinator (Spain)
UPF was established in 1990 as a public university with a strong dedication to excellence in research and teaching. UPF is the 1st Spanish university in the world Top 200 (THE20), also ranked 2nd in Europe (U-Multirank 2020) and 1st in Spain in teaching and research performance (U-Ranking, BBVA Foundation & Ivie, 2019). UPF takes part in this proposal through its ICT Department (DTIC), which has over 60% of international researchers from 48 different countries. It is strategically located within the vibrant [email protected] technological district of Barcelona. It has been recognized as “María de Maeztu” unit of excellence by the Spanish government for the quality and relevance of its pioneering scientific research. BCN-MedTech has a team of 60 full time researchers focused on developing tools for medical image analysis, computer-aided diagnosis, and treatment planning, as well as on their applications to relevant clinical problems and industrial products.
INSILICOTRIALS TECHNOLOGIES S.R.L. (Italy)
InSilicoTrials was founded in 2012 (with the original name of Promeditec) to offer innovative solutions and specialized consultancy for clinical trials. In 2016, a new business line towards the technological support of in silico clinical trials was developed. Today, the goal of InSilicoTrials is to fuel innovations in healthcare by creating a collaborative platform that enables widespread exploitation of highly advanced modeling and simulations (M&S) tools. Building upon a strong base of research and industrial collaborations, InSilicoTrials has furthered its position as innovative solution for broad-scale use of highly valuable in silico tools since its establishment as independent company.
InSilicoTrials harbors a diverse and balanced team with extensive expertise and know-how on M&S, medical product R&D, management, regulations and software development.
BARCELONA SUPERCOMPUTING CENTER - CENTRO NACIONAL DE SUPERCOMPUTACION (Spain)
The Barcelona Computing Center (BSC) BSC is a public research centre created in 2005 and devoted to enhance research in many different fields by providing HPC resources to different communities, and by directly generating knowledge in different areas, such as computing, earth, life sciences and Computer Applications in Science and Engineering. It hosts the MareNostrum 4, one of the PRACE (European supercomputing infrastructure) supercomputers. BSC was selected in June 2019 by EuroHPC as one of the three institutions to host a pre-exascale supercomputer in the high-capacity supercomputer network that will operate in the EU by 2021.The Life Sciences Department integrates the independent research of senior scientists that work on various aspects of computational biology, ranging from bioinformatics for genomics to computational biochemistry and text mining.
OULUN YLIOPISTO (Finland)
The University of Oulu (OULU) is a non-profit, higher education providing organization funded largely by the Finnish government. OULU has 16 000 students and 3000 staff members and is ranked the 2nd best university in Finland (Academic Ranking of World Universities). Life-long health is one of the five research focus areas of the university strategy. In addition, Digital Health is one of UOULU’s profilation themes, funded by the Academy of Finland. The faculty of Medicine is situated in conjunction with the University Hospital and the Faculty of Biochemistry and Molecular Medicine. The faculty encompasses 12 research units with most research groups being affiliated also to either the Medical Research Center (MRC) or Biocenter Finland, multidisciplinary umbrella organizations. The Medical Research Center (MRC) is a strategic research organization of the Northern Ostrobothnia Hospital District and the OULU closely integrating clinical aspects from the hospital to the university area.
GALGO MEDICAL (Spain)
GALGO MEDICAL (GALGO) is a post-processing medical imaging company that develops software products in three main domains: advanced diagnosis in osteoporosis and fracture risk, planning and guiding of heart ablation procedures, and cerebral braided stents planning.
KING’S COLLEGE LONDON (UK)
King’s College London is one of the world’s leading research and teaching institutions. In the 2017-2018 QS international world rankings, King’s was ranked as one of the top 25 universities in the world. In the 2014 Research Excellence Framework (REF) King’s was ranked 6th nationally in the ‘power’ ranking, which takes into account both the quality and quantity of research activity, and eighty-four per cent of research at King’s was deemed ‘world-leading’ or ‘internationally excellent’ (3* and 4*).
The Faculty of Life Sciences & Medicine is one of the largest and most successful centres for research and education in the UK. 91.8 percent of the Faculty's REF 2014 submission was rated 4 star or 3 star.
The Department of Twin Research & Genetic Epidemiology (DTR) is a grant funded department conducting genetic research in to complex diseases in particular age-related diseases, including osteoporosis, diabetes, obesity, cardiovascular, musculoskeletal and eye diseases. The DTR also conducts clinical trials and research into miscellaneous areas such dermatology, immunology, gastroenterology and behaviour and lifestyle; resulting in publications in leading scientific journals. The DTR has a strong record in data sharing with the wider scientific community leading to 700 collaborative projects since 2010 and over 500 publications. Our 70-80 publications annually from TwinsUK are highly cited and have an H factor of over 100 and include all the top Journals – Nature, Science, Cell, Lancet, New England Journal etc. and was ranked in the top 1% of cited research groups globally in 2015.
SHEFFIELD HALLAM UNIVERSITY (UK)
Sheffield Hallam University is a large University with over 25,000 students. It has a focussed strategy towards research and concentrates its activities into Research Centres of excellence. Sheffield Hallam University's research programme was ranked in the top five of all UK modern universities in the national Research Excellence Framework (REF) 2014. The university holds a HR Excellence in Research Award – only 207 of the 3,330 universities in the EU have been recognised with this award. Presented by the European Commission, the award demonstrates a university's commitment to improving the working conditions and career development for research staff, which will in turn improve the quantity, quality and impact of research for the benefit of UK society and the economy. The Athena SWAN Charter recognizes excellence in an institution’s commitment to gender equality. SHU holds a Bronze institutional award and the Biomolecular Sciences Research Centre (BMRC) holds a Silver award. SHU will lead ESR 7 investigating the presence of the bacteria in native human IVD disc tissue, and identifying the potential influence on native disc cells and thus its role in the pathogenesis of disc degeneration.
FUNDACIÓ INSTITUT MAR D'INVESTIGACIONS MÈDIQUES (Spain)
The Fundació Institut Mar d’Investigacions Mèdiques (IMIM) is a biomedical research institute that manages the translational and clinical research carried out by the Parc de Salut Mar, a public healthcare organisation located in Barcelona. The IMIM is located in the Barcelona Biomedical Research Park (PRBB). IMIM will take part in the project through the Research Programme on Biomedical Informatics, GRIB (http://grib.imim.es/), which is a joint programme of IMIM and Universitat Pompeu Fabra (UPF). GRIB carries out methodological research and technological developments on the application of advanced information technologies and computational methods in the health and life sciences. GRIB has a long record of leadership and participation in EU-funded projects and collaboration with pharmaceutical industry in knowledge management, translational bioinformatics and predictive modelling.GRIB staff is involved in pre and postgraduate teaching at the UPF and we are coordinators of the Master in Bioinformatics for Health Sciences. Two groups of the GRIB are participating in the project: the Integrative Biomedical Informatics group, led by Ferran Sanz and Laura Furlong and the Structural Bioinformatics Group, led by Baldo Oliva.
UNIVERSITÄT BERN (Switzerland)
The host institution will be the department for BioMedical Research (DBMR) and the Department for Orthopaedic Surgery and Traumatology, University of Bern (UBERN). With 18,250 students and 3,000 PhD students, UBERN is the third largest university in Switzerland and is ranked 113 in the 2020 Times World University Rankings. UBERN hosts several internationally well-recognized research centers, such as the ARTORG Center for Biomedical Engineering Research, and “MUST”, the National Centre of Competence in Research on Molecular Ultrafast Sciences and Technology, co-hosted with the ETH Zurich. UBERN is very experienced in managing EU Grants and has been involved in many projects since FP3. For FP7 and Horizon 2020, this amounts to about 130 and 60 grants, respectively. UBERN has endorsed the “The European Charter for Researchers” and “The Code of Conduct for the Recruitment of Researchers”. European grants are managed by the Euresearch office, which is part of the Grants Office. The Medical Faculty of the University Bern, together with the University Hospital Bern (Insel) and affiliated research institutes, is recognized as a leader in medical research. In the context of its current strategy, the UBern has identified medical technology as a particularly important development focus, a decision based on the leading role of its clinical interventional disciplines and the strong presence of the medical technology industry in the greater Bern area. It has been decided to establish a medical technology platform termed “Biomedical Engineering Research of the Canton of Bern”.) The Department for BioMedical Research (DBMR) has a long reputation to attract large-scale support from the Swiss National Science Foundation (NSF) but also from EU Projects.
PROTATONCE LTD (Greece)
ProtATonce (PAO) is a drug discovery solutions provider for biomarker and target analysis. Using proprietary Systems Pharmacology approaches, ProtATonce combines state-of-the-art facilities for the generation of multi-omics data (proteomic, genomic, and transcriptomic data) and a strong computational platform for data integration and analysis. Since its establishment in 2012, PAO was able to partnership with leading companies worldwide, generate revenue to break-even from $1M start-up cost, and deliver viable solutions for drug discovery. The main source of PAO’s income is the private sector via contracts with industry. The list of partners includes IBM Research, Roche, Harvard Medical School, and many more. PAO has unique expertise and IP to develop and manufacture antibody based multiplex assays. More than 1000 assays have been built which gives PAO an unparalleled ability to screen the intracellular (phosphoprotein) and secretome profile of in-vitro cellular systems. PAO’s service contracts have included i) translation of drug effects between rat and human models, ii) Biomarker discovery for diagnosis of chronic kidney disease, and iii) identification of optimal drug combination treatments for Multiple Sclerosis. PAO is closely following the commercial trends of the pharmaceutical and diagnostics industry and has the goal to become a world leader niche service provider for early drug discovery and diagnostics.
UNIVERSITÉ DE LIÈGE (Belgium)
The University of Liege is fully part of the European and International higher education and research area and is the only public and complete university institution of the French-speaking region of Belgium. The ULiege counts 3000 lecturers-researchers and 23.800 students (23% of international origin). ULiege pays special attention to HR Strategy for Researchers which guarantees the quality of the training and administrative support given to PhD candidates (among others). ULiege is also fully commited in hosting incoming researchers and in Open Access/Science. The Biomechanics Research Unit from the GIGA In silico medicine division focusses on developing computer models of skeletal tissue engineering processes. These models range from intracellular over tissue to population scale. In vitro fluidics set-ups (meso/macrofluidics) are developed and used to study tissue engineering processes. The unit operates in close collaboration with clinicians in the University Hospitals of Liège and KU Leuven. The unit currently counts 18 researchers (PhD students, postdocs, a technical engineer and a data scientist).